It is hypothesised that the use of intra-operative ultrasonography in the excision of palpable breast cancer compared with the standard palpation-guided surgery will improve the ability to spare healthy breast tissue while maintaining or even…
ID
Bron
Verkorte titel
Aandoening
Breast cancer, breast-conserving surgery, palpable, intra-operative ultrasonography, excision volume, cosmetic outcome, margin status, quality of life
Borstkanker, mammasparende chirurgie, palpabel ammacarcinoom, intra-operatieve echografie, excisievolume, cosmetiek, radicaliteit, kwaliteit van leven
Ondersteuning
Dept. of Surgical Oncology
Prof.dr. J. bonjer, prof.dr. S. Meijer
De Boelelaan 1117
1081 HV Amsterdam
The Dutch Pink Ribbon breast cancer foundation
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
1. Excision volume;<br>
2. Margin status.
Achtergrond van het onderzoek
Breast-conserving therapy (BCT) for breast cancer is initiated as a method to preserve healthy breast tissue, thereby improving cosmetic outcomes. The cosmetic outcome after breast cancer surgery is an important determinant of patient satisfaction, maintenance of self-image and quality of life. Thus far, the primary aim of BCT has been focused on achieving tumour-free resection margins and preventing local recurrence, while the cosmetic outcome has been considered less important. Large studies have reported poor cosmetic outcomes in 20-40% of patients after BCT, and the volume of resected breast tissue is the major determinant of the cosmetic outcome. In daily practice, surgical resection of palpable breast cancer is performed with guidance by intra-operative palpation. Concerns about tumour involvement of resection margins, however, often result in unnecessarily wide resection of adjacent healthy breast tissue. Our recent large multicentre retrospective study showed that in 32% (112/351) of patients over 200% excessive healthy breast tissue was excised with the malignant tissue! The mean volume excessively excised was 142 cm³ (64-423 cm³; sd 86)! There is clear evidence for the efficacy of ultrasonography (US) in the resection of nonpalpable tumours, and US is an easy available and feasible method for continuous visualisation during surgery. Intra-operative US reduces the resection of healthy breast tissue and improves tumour-free resection margins. In the present study, the value of the use of US during the resection of palpable tumours of the breast will be investigated. The objectives will be to determine whether US-guided resection of palpable breast cancer allows sparing of the breast tissue while preserving tumour-free resection margins with improvements in cosmetic outcomes and quality of life.
Doel van het onderzoek
It is hypothesised that the use of intra-operative ultrasonography in the excision of palpable breast cancer compared with the standard palpation-guided surgery will improve the ability to spare healthy breast tissue while maintaining or even improving the oncological margin status.
Onderzoeksopzet
The inclusion period will run from October 2010 to July 2011.
The EORTC QLQ-C30/-BR23 questionnaire will be completed by the patient prior to surgery. Surgery will be scheduled 1-2 weeks after diagnosis.
During a follow-up visit to the outpatient clinic, usually 1-2 weeks after discharge, complications will be recorded and treated.
Three and six months after surgery, information will be collected from each patient concerning the cosmetic outcome and quality of life, and photographs will be taken.
Patients can withdraw from the study at any time during the study period.
Onderzoeksproduct en/of interventie
The use of intra-operative ultrasonography in the breast-conserving surgery for palpable breast cancer.
Control: The standard palpation-guided breast-conserving surgery (no use of intra-operative visualisation).
Publiek
De Boelelaan 1117
Nicole M.A. Krekel
Amsterdam 1081 HV
The Netherlands
+31 (0)20 4440829
n.krekel@vumc.nl
Wetenschappelijk
De Boelelaan 1117
Nicole M.A. Krekel
Amsterdam 1081 HV
The Netherlands
+31 (0)20 4440829
n.krekel@vumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Women age 25-75 yrs who are diagnosed with palpable early-stage (T1-2N0-1) primary breast cancer in the trial centres. Breast cancer will be diagnosed with physical examination, mammography (2R) and US of the breast and axilla. The diagnosis of invasive (ductal or lobular) breast cancer will be established with image-guided core needle biopsy or cytological puncture;
2. All patients will be suitable for BCT according to national guidelines;
3. Participants will not have a history of prior mammary surgery in the affected breast, radiation therapy or neo-adjuvant therapy;
4. Participants will have ASA Classification I – III;
5. Participants will be well-informed having signed an informed consent form.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Participants with a history of prior mamma surgery, radiation therapy or neo-adjuvant therapy;
2. Patients younger than 25 years;
3. Patients age above 75 years.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL2463 |
NTR-old | NTR2579 |
CCMO | NL31664.029.10 |
ISRCTN | ISRCTN wordt niet meer aangevraagd. |
OMON | NL-OMON36758 |